Price$7.35-4.78 (-39.41%)
2026-07-162026-10-16
News · 26 weeks58+367%
2026-04-192026-10-11
Mix2890d
- Insider11(39%)
- Other10(36%)
- SEC Filings4(14%)
- Analyst1(4%)
- Market1(4%)
- Leadership1(4%)
Latest news
25 items- INSIDERSEC Form 4 filed by Akari Therapeutics plc4 - Akari Therapeutics Plc (0001541157) (Issuer)
- INSIDERSEC Form 4 filed by Akari Therapeutics plc4 - Akari Therapeutics Plc (0001541157) (Issuer)
- INSIDERSEC Form 4 filed by Akari Therapeutics plc4 - Akari Therapeutics Plc (0001541157) (Issuer)
- INSIDERSEC Form 4 filed by Akari Therapeutics plc4 - Akari Therapeutics Plc (0001541157) (Issuer)
- INSIDERSEC Form 4 filed by Akari Therapeutics plc4 - Akari Therapeutics Plc (0001541157) (Issuer)
- INSIDERSEC Form 4 filed by Akari Therapeutics plc4 - Akari Therapeutics Plc (0001541157) (Issuer)
- PRAkari Therapeutics CEO Highlights Differentiated ADC Payload Strategy and Path Toward Clinical Development in New CEO CornerCEO Abizer Gaslightwala discusses Akari’s novel PH1 payload strategy and execution priorities supporting AKTX-101’s advancement toward planned Phase 1 clinical development in mid-2027 Recent deal activity and emerging clinical data highlighting limitations of current ADC sequencing reinforce the increasing demand for novel ADC payloads Access the Akari CEO Corner here TAMPA, Fla. and LONDON, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with a novel RNA splicing disrupting payload, today released a new CEO Corner segment featuring President and Chief Executive Officer Abizer Gaslight
- INSIDERSEC Form 4 filed by Akari Therapeutics plc4 - Akari Therapeutics Plc (0001541157) (Issuer)
- INSIDERSEC Form 3 filed by Akari Therapeutics plc3 - Akari Therapeutics Plc (0001541157) (Issuer)
- PRAkari Therapeutics Appoints Accomplished Oncology and ADC Deal Executive Vatnak Vat-Ho as Chief Business Officer to Drive Strategic Growth and PartneringMr. Vat-Ho's appointment adds more than 20 years of oncology, biopharma and capital markets experience, including senior roles in transactions totaling more than $25 billion in aggregate value Mr. Vat-Ho brings highly relevant ADC payload partnering experience, including recently executed collaborations with Exelixis and BioNTech TAMPA, Fla. and LONDON, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with a novel RNA splicing disrupting payload, today announced the appointment of Vatnak Vat-Ho as Chief Business Officer, strengthening the Company’s leadership team with an accomplished onc
- SECSEC Form DEF 14A filed by Akari Therapeutics plcDEF 14A - Akari Therapeutics Plc (0001541157) (Filer)
- INSIDERCEO Gaslightwala Abizer was granted 6,430 units of American Depositary Shares representing Ordinary Shares, increasing direct ownership by 84% to 14,107 units (SEC Form 4)4 - Akari Therapeutics Plc (0001541157) (Issuer)
- SECAkari Therapeutics plc filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Akari Therapeutics Plc (0001541157) (Filer)
- PRAkari Therapeutics Expands Intellectual Property Portfolio with PCT Filing for ADC Payload Related to RNA Splicing in CancersPatent filing covers PH1 payload’s unique ability to disrupt multiple cancer-driving pathways in addition to its overall cytotoxic mechanism Expands intellectual property portfolio supporting Akari’s novel payload and ADC platform TAMPA, Fla. and LONDON, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with a novel RNA splicing disrupting payload, today announced the filing of PCT/US2026/45955, expanding the Company’s growing intellectual property portfolio around its novel splicing-modulating payload, PH1 and PH1-based ADCs. Alternative splicing enables cells to generate different pro
- PRAkari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare ForumsCompany invited to present alongside global pharmaceutical, biotechnology and industry leaders at five high-profile U.S. and China conferences in September CEO Abizer Gaslightwala to deliver keynote and featured presentations on next-generation ADC payload innovation and partnerships/collaborations TAMPA, Fla. and LONDON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced that the Company has been selected to participate in five prominent oncology, ADC and healthcare industry and investor conferences in the United States and Chin
- PRAkari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand ConferenceVideo webcast now available here TAMPA, Fla. and LONDON, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced that it participated in the Virtual Investor "Why Now" on-demand conference. During the webcast, Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics, presented the Company's investment thesis, highlighting why he believes now is a pivotal time for Akari. The discussion highlights the rapidly evolving ADC landscape, increasing industry demand for differentiated payload technologies, and Akari's pro
- NEWSJTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOsNine CEOs. Nine investment stories. 60 seconds each to answer the question that matters most to investors: Why now?On-demand video series gives investors rapid access to company leadership, recent milestones, upcoming catalysts and the opportunities management believes investors should be watching todayAccess on demand conference here FRENCHTOWN, NJ / ACCESS Newswire / August 27, 2026 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced the release of its Virtual Investor "Why Now" On-Demand Conference, featuring a fast-paced series of 60-second presentations from the CEOs of nine publicly traded companies.The premise is simple: Why sho
- INSIDERInterim CFO Farag Kameel D. was granted 1,728 units of American Depositary Shares representing Ordinary Shares, increasing direct ownership by 8% to 23,309 units (SEC Form 4)4 - Akari Therapeutics Plc (0001541157) (Issuer)
- PRAkari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC StrategyAKTX-101 demonstrated robust anti-tumor activity across multiple clinically relevant urothelial cancer preclinical models Data supports the potential of Akari’s novel PH1 RNA spliceosome-modulating payload to overcome payload-specific resistance Results strengthen the rationale for a differentiated ADC sequencing strategy as ADC use expands across oncology and more patients require treatment following relapse Akari advancing IND-enabling activities for AKTX-101 toward planned Phase 1 clinical development in mid-2027 TAMPA, Fla. and LONDON, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADC
- PRAkari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload PlatformAKTX-101 advancing through IND-enabling development activities toward planned initiation of Phase 1 clinical trial in mid-2027 Compelling ASCO 2026 preclinical data further differentiates PH1 mechanism in KRAS-mutated pancreatic cancer models Strategic research collaboration with Whitehawk Therapeutics expands potential application of Akari’s PH1 platform into dual-payload ADCs Balance sheet strengthened by approximately $8.6 million of financing during the quarter, led by long-term strategic investors TAMPA, Fla. and LONDON, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with a novel
- SECAkari Therapeutics plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Akari Therapeutics Plc (0001541157) (Filer)
- SECSEC Form 10-Q filed by Akari Therapeutics plc10-Q - Akari Therapeutics Plc (0001541157) (Filer)
- SECSEC Form SCHEDULE 13G filed by Akari Therapeutics plcSCHEDULE 13G - Akari Therapeutics Plc (0001541157) (Subject)
- INSIDERInterim CFO Farag Kameel D. was granted 1,130 units of American Depositary Shares representing Ordinary Shares, increasing direct ownership by 6% to 21,581 units (SEC Form 4)4 - Akari Therapeutics Plc (0001541157) (Issuer)
- PRAkari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC InnovationDiscussion explores how combining complementary payload technologies may unlock new therapeutic opportunities while reinforcing the versatility of Akari's proprietary PH1 spliceosome-modulating payload platform Access the Akari CEO Corner here TAMPA, Fla. and LONDON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today released a new CEO Corner segment featuring President and Chief Executive Officer Abizer Gaslightwala discussing the Company's recently announced strategic research collaboration with WhiteHawk Therapeutics and why the Company b
AKTX FAQ
6 questionsWhat does Akari Therapeutics plc do?
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for autoinflammatory diseases that involve complement and leukotriene pathways. Its lead product candidate is nomacopan, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in...Where does AKTX stock trade?
Akari Therapeutics plc (AKTX) is listed on NASDAQ.What sector and industry is AKTX in?
Akari Therapeutics plc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about AKTX?
Akari Therapeutics plc has had 4 recent analyst actions on file. The most recent action was from Maxim Group: Buy with a $3000.00 price target on 2026-07-20.What companies are similar to AKTX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare AKTX side-by-side with any of them on Quantisnow.How can I track AKTX on Quantisnow?
Quantisnow aggregates Akari Therapeutics plc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AKTX to receive live email and push alerts on every new disclosure.